You are here

3D Microfluidic Platform for in vitro Hematopoietic Stem Cell (HSC) Culture

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-10-P-0038
Agency Tracking Number: C101-103-0016
Amount: $99,983.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD10-103
Solicitation Number: 2010.1
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-05-17
Award End Date (Contract End Date): 2010-11-16
Small Business Information
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
United States
DUNS: 153865951
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Mahsa Rouhanizadeh
 Research Scientist
 (310) 320-3088
 psproposals@poc.com
Business Contact
 Gordon Drew
Title: Chief Financial Officer
Phone: (310) 320-3088
Email: gedrew@poc.com
Research Institution
N/A
Abstract

To address the Chemical/Bio Defense (CBD) need for in vitro models suitable for high-throughput screening of drug toxicities in human tissues, Physical Optics Corporation (POC) proposes to develop a new three-dimensional (3D) Microfluidic Platform for in-vitro Hematopoietic Stem Cell (HSC) Culture (3D-Mic-Stem). This proposed system is based on a 3D microfluidic design that uses HSCs for assaying high-throughput drug toxicities. The innovation in the 3D microfluidic implementation for stem cell culture and accompanying mitochondrial functionality assay, with the toxicity assay, will enable the system to validate precisely the drug screening process. As a result, this system offers high-throughput screening adaptability, as well as amenability to integration into the system biology architecture. In addition, the human HSCs represent tissue types relevant to toxicological end points, directly addressing the CBD/TMTI program’s requirements. In Phase I, POC will demonstrate the feasibility of 3D-Mic-Stem for drug toxicity screening by designing a proof-of-concept study of the 3D microfluidic culture of HSCs. In Phase II, POC plans to develop initial proof-of-concept studies using drugs with known toxicities and interactions as validation.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government